[go: up one dir, main page]

CY2501B1 - Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents. - Google Patents

Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.

Info

Publication number
CY2501B1
CY2501B1 CY0500008A CY0500008A CY2501B1 CY 2501 B1 CY2501 B1 CY 2501B1 CY 0500008 A CY0500008 A CY 0500008A CY 0500008 A CY0500008 A CY 0500008A CY 2501 B1 CY2501 B1 CY 2501B1
Authority
CY
Cyprus
Prior art keywords
benzodioxane
benzodioxole
dihydrobenzofuran
benzofuran
melatonergic agents
Prior art date
Application number
CY0500008A
Other languages
English (en)
Inventor
John D Catt
Graham Johnson
Daniel J Keavy
Ronald J Mattson
Michael F Parker
Katherine S Takaki
Joseph P Yevich
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CY2501B1 publication Critical patent/CY2501B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D321/00—Heterocyclic compounds containing rings having two oxygen atoms as the only ring hetero atoms, not provided for by groups C07D317/00 - C07D319/00
    • C07D321/02—Seven-membered rings
    • C07D321/10—Seven-membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY0500008A 1996-12-10 2005-01-31 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents. CY2501B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3268996P 1996-12-10 1996-12-10

Publications (1)

Publication Number Publication Date
CY2501B1 true CY2501B1 (en) 2005-09-02

Family

ID=21866306

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0500008A CY2501B1 (en) 1996-12-10 2005-01-31 Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.

Country Status (25)

Country Link
US (3) US5856529A (fr)
EP (1) EP1027043B1 (fr)
JP (1) JP4290765B2 (fr)
KR (1) KR100499106B1 (fr)
CN (1) CN1152679C (fr)
AR (1) AR010346A1 (fr)
AT (1) ATE281833T1 (fr)
AU (1) AU719994B2 (fr)
BR (1) BR9713690B1 (fr)
CA (1) CA2274183C (fr)
CY (1) CY2501B1 (fr)
CZ (1) CZ297673B6 (fr)
DE (1) DE69731562T2 (fr)
DK (1) DK1027043T3 (fr)
ES (1) ES2230626T3 (fr)
HU (1) HU226524B1 (fr)
IL (1) IL129999A (fr)
NO (1) NO321450B1 (fr)
NZ (1) NZ335910A (fr)
PL (1) PL190499B1 (fr)
PT (1) PT1027043E (fr)
RU (1) RU2190609C2 (fr)
TW (1) TW476758B (fr)
WO (1) WO1998025606A1 (fr)
ZA (1) ZA9711051B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9614347D0 (en) * 1996-07-09 1996-09-04 Smithkline Beecham Spa Novel compounds
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
AU740554B2 (en) * 1998-06-05 2001-11-08 Bristol-Myers Squibb Company Heterocyclic cis cyclopropane derivatives as melatonergic agents
AU763963B2 (en) * 1999-06-30 2003-08-07 Bristol-Myers Squibb Company Heterocyclic aminopyrrolidine derivatives as melatonergic agents
MXPA03010435A (es) 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
CA2461381A1 (fr) * 2001-10-04 2003-04-10 Wyeth Derives du chroman, ligands de l'5-hydroxytryptamine-6
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
US6737431B2 (en) 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
WO2004005266A1 (fr) * 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Derives oxazole et utilisation de ceux-ci en tant que sensibilisateurs a l'insuline
MXPA05002115A (es) * 2002-08-30 2005-05-23 Hoffmann La Roche Compuestos novedosos de 2-ariltiazol como agonistas de pparalfa y ppargama.
DK1539746T3 (da) * 2002-09-12 2007-03-26 Hoffmann La Roche N-substituerede 1H-indol-5-propionsyre-forbindelser som PPAR-agonister der er nyttige til behandling af diabetes
ATE405560T1 (de) * 2002-11-25 2008-09-15 Hoffmann La Roche Indolderivaten
WO2004059900A2 (fr) * 2002-12-17 2004-07-15 Evolution Robotics, Inc. Systemes et procedes de localisation et de cartographie visuelles simultanees
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
US20090209638A1 (en) * 2006-05-22 2009-08-20 Gunther Birznieks Treatment for depressive disorders
KR101587394B1 (ko) * 2006-05-22 2016-01-21 반다 파마슈티칼즈, 인코퍼레이티드. 멜라토닌 효능제 치료
BRPI0810997A2 (pt) 2007-04-26 2015-01-27 Takeda Pharmaceutical Composto, pró-droga, composição farmacêutica, método para prevenir ou tratar distúrbio do sono em um mamífero, e, uso do composto
US7964430B2 (en) * 2007-05-23 2011-06-21 Applied Materials, Inc. Silicon layer on a laser transparent conductive oxide layer suitable for use in solar cell applications
WO2009036257A1 (fr) * 2007-09-13 2009-03-19 Vanda Pharmaceuticals, Inc. Prévision d'un paramètre du sommeil et de la réponse à un composé induisant le sommeil à base du génotype du minisatellite (vntr) per3
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
EP2287159A1 (fr) * 2009-07-29 2011-02-23 V.Mane Fils Nouveaux dioxanes bicycliques, leur préparation et leur utilisation en tant que composés organoleptiques
EP2626350B1 (fr) * 2010-09-22 2015-04-15 Eisai R&D Management Co., Ltd. Composé de cyclopropane
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (fr) 2011-01-28 2012-08-02 Zx Pharma, Llc Composition de mélatonine à libération contrôlée et procédés associés
WO2013112949A2 (fr) 2012-01-26 2013-08-01 Vanda Pharmaceuticals Inc. Traitement de troubles du rythme circadien
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
KR101891299B1 (ko) 2012-05-18 2018-08-23 반다 파마슈티칼즈, 인코퍼레이티드. (1ｒ-트랜스)-ｎ-[[2-(2,3-디하이드로-4-벤조푸라닐)시클로프로필]메틸]프로판아미드의 대사 산물
AR091699A1 (es) 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
JPWO2014010603A1 (ja) * 2012-07-10 2016-06-23 アステラス製薬株式会社 腹圧性尿失禁又は混合型尿失禁の治療又は予防用医薬組成物、及び該医薬組成物に含有される化合物のスクリーニング方法
EP3767297A1 (fr) 2012-12-18 2021-01-20 Vanda Pharmaceuticals Inc. Traitement des troubles du rythme circadien
US9643947B2 (en) 2013-08-28 2017-05-09 Northwestern University 7-membered fused heterocycles and methods of their synthesis
US9573921B2 (en) * 2013-09-30 2017-02-21 Polfarmex S.A. Substituted N, N-dimethylaminoalkyl ethers of isoflavanone oximes as H1-receptor antagonists
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
WO2015117048A1 (fr) 2014-01-31 2015-08-06 Vanda Pharmaceuticals Inc. Traitement de troubles du rythme circadien
US12304896B2 (en) 2014-12-04 2025-05-20 Vanda Pharmaceuticals Inc. Highly purified pharmaceutical grade tasimelteon
WO2015123389A1 (fr) 2014-02-12 2015-08-20 Vanda Pharmaceuticals Inc. Tasimeltéon de qualité pharmaceutique, hautement purifié
AU2015312252B2 (en) 2014-09-02 2020-07-02 Vanda Pharmaceuticals Inc. Tasimelteon for treating Smith-Magenis Syndrome
CN104327022B (zh) * 2014-10-17 2015-12-02 苏州明锐医药科技有限公司 他司美琼的制备方法
CN104402849B (zh) * 2014-11-11 2016-11-09 苏州莱克施德药业有限公司 他司美琼中间体的新制备工艺
CN106588841B (zh) * 2015-10-19 2019-01-25 富乐马鸿凯（大连）医药有限公司 合成2,3-二氢-1-苯并呋喃-4-甲醛的方法
RU2018142019A (ru) 2016-05-06 2020-06-08 ФИЗИШН`С СИЛ, ЭлЭлСи Валериановая композиция и соответствующие способы
CN105949153B (zh) * 2016-05-10 2018-03-02 浙江工业大学 一种他司美琼的合成方法
CN107365288A (zh) * 2016-05-12 2017-11-21 浙江京新药业股份有限公司 他司美琼的晶型
US9944616B2 (en) 2016-06-08 2018-04-17 Apotex Inc. Processes for the preparation of Tasimelteon and intermediates thereof
CN106543119B (zh) * 2016-09-22 2019-07-26 浙江工业大学 一种光学纯他司美琼的制备方法
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
WO2018149940A1 (fr) 2017-02-17 2018-08-23 Quimica Sintetica, S. A. Procédé de préparation de dihydrobenzofuranes enrichis de manière énantiomérique et composés intermédiaires obtenus durant le procédé
EP3661494B8 (fr) 2017-08-02 2023-11-22 Vanda Pharmaceuticals Inc. Utilisation de tasimeltéon pour le traitement de troubles affectifs cehz patients en majorité noir africains
WO2019173180A1 (fr) * 2018-03-04 2019-09-12 Vanda Pharmaceuticals Inc. Traitement de troubles avec tasimelteon
KR20210060489A (ko) * 2018-09-12 2021-05-26 반다 파마슈티칼즈, 인코퍼레이티드. 수면 또는 수면 후 거동 개선
ES3013667T3 (en) 2019-05-15 2025-04-14 Eisai R&D Man Co Ltd Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities
CA3145247A1 (fr) 2019-06-29 2021-01-07 Vanda Pharmaceuticals Inc. Utilisation de tasimelteon dans le traitement d'aberrations du sommeil
CN114727978A (zh) 2019-12-13 2022-07-08 万达制药公司 液体他司美琼制剂及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2667316B1 (fr) * 1990-10-02 1994-09-16 Roussel Uclaf Nouveaux derives du benzofuranne, leur procede de preparation et leur application comme pesticides.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680507B1 (fr) * 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) * 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
FR2725985B1 (fr) * 1994-10-21 1996-11-15 Adir Nouveaux composes tricycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5633218A (en) * 1995-05-24 1997-05-27 E. I. Du Pont De Nemours And Company Herbicidal benzodioxoles and benzodioxanes
CA2176854A1 (fr) * 1995-06-07 1996-12-08 Daniel J. Keavy Derives de n-acyl-2-arylcyclopropylmethylamine, agents melatonergiques
US5596019A (en) * 1995-06-07 1997-01-21 Bristol-Myers Squibb Company N-acyl-cycloalkylamine derivatives as melatonergics
WO1997043272A2 (fr) * 1996-05-14 1997-11-20 Glaxo Group Limited Benzofurans et benzopyrans utilises en tant qu'agents chronobiologiques

Also Published As

Publication number Publication date
CZ297673B6 (cs) 2007-02-28
EP1027043B1 (fr) 2004-11-10
NZ335910A (en) 2000-11-24
CZ199199A3 (cs) 1999-09-15
IL129999A0 (en) 2000-02-29
CN1239886A (zh) 1999-12-29
EP1027043A1 (fr) 2000-08-16
NO992804L (no) 1999-08-09
PT1027043E (pt) 2005-02-28
PL333950A1 (en) 2000-01-31
JP4290765B2 (ja) 2009-07-08
HUP0000695A2 (hu) 2001-05-28
AU719994B2 (en) 2000-05-18
PL190499B1 (pl) 2005-12-30
DE69731562D1 (de) 2004-12-16
CN1152679C (zh) 2004-06-09
ATE281833T1 (de) 2004-11-15
ES2230626T3 (es) 2005-05-01
HU226524B1 (en) 2009-03-30
BR9713690A (pt) 2000-05-02
NO321450B1 (no) 2006-05-15
DK1027043T3 (da) 2005-01-10
CA2274183C (fr) 2006-10-24
ZA9711051B (en) 1999-06-09
HK1029947A1 (en) 2001-04-20
NO992804D0 (no) 1999-06-09
DE69731562T2 (de) 2005-11-24
TW476758B (en) 2002-02-21
JP2001505916A (ja) 2001-05-08
IL129999A (en) 2004-06-20
BR9713690B1 (pt) 2009-08-11
AU5598598A (en) 1998-07-03
WO1998025606A1 (fr) 1998-06-18
KR20000069396A (ko) 2000-11-25
EP1027043A4 (fr) 2002-02-20
RU2190609C2 (ru) 2002-10-10
US5856529A (en) 1999-01-05
AR010346A1 (es) 2000-06-07
KR100499106B1 (ko) 2005-07-01
US5981571A (en) 1999-11-09
US6060506A (en) 2000-05-09
CA2274183A1 (fr) 1998-06-18
HUP0000695A3 (en) 2002-09-30

Similar Documents

Publication Publication Date Title
CY2501B1 (en) Benzodioxole, benzofuran, dihydrobenzofuran, and benzodioxane melatonergic agents.
ZA9811081B (en) (Benzodioxan, Benzofuran or Benzopyran) Derivatives having fundic relaxation properties.
ID22271A (id) Turunan-turunan 2-(purin-9-il) tetrahidrofuran-3,4-diol
NO2005009I2 (no) Emselex-darifenacin. Iupac-navn: (S)-2-ä1-Ä2-(2,3 -dihydrobenzofuran-5-yl)etylÜ-3-pyrrolidinylü-2,2-difenylacetamid
TR199700090A2 (tr) Yeni heteroaril-oksazolidinonlar.
PH31295A (en) Ä(Benzodioxan, benzofuran or benzopyran)alkylaminoÜalkyl substituted guanidines.
ZA200000865B (en) Dicarboalkoxy dioxolanes.
DK0901483T3 (da) Benzofuraner og benzopyraner som kronobiologiske midler
FI952823A7 (fi) Aminometyyli-indaanit, -bentsofuraanit ja -bentsotiofeenit
FR2719937B1 (fr) Dispositif modérateur de son.
ATE203528T1 (de) Antineurodegenerativ wirksame 10-aminoaliphatyl- dibenz- b,f oxepine
BR9917018B1 (pt) estrutura compósita protetora.
HUP9902901A3 (en) Substituted 1,2,3,4-tetrahydro-2-dibenzofuranamines and 2-aminocyclohepta[b]benzofurans
HUP0104510A3 (en) Benzofuran derivatives, their preparation and use
ITTO960041A0 (it) Macchina semovente per la stabilizzazione, mediante martellinatura e compattazione, di binari posati su massicciata.
DE69737265D1 (de) Herstellung nickelenthaltenden, gesinterten, verfestigten, feritischen rostfreien stahls
IL133919A0 (en) 2,4,4-trisubstituted-1,3-dioxolane antifungals
NL1004459A1 (nl) Geluidwerende elementen.
IL126780A0 (en) Substituted 1,3-benzodioxoles
ES1035719Y (es) Pantalla de proteccion facial, desechable.
ZA200103987B (en) Benzofuran derivatives, their preparation and use.
SI0901483T1 (en) Benzofurans and benzopyrans as chronobiological agents
ES1037296Y (es) Juego de construccion, dinamico.
ZA974375B (en) Benzofuran carboxamides and their therapeutic use.
ZA9610242B (en) Benzofuran carboxamides and sulphonamides.